The course and outcomes of COVID-19 in patients with ANCA-associated systemic vasculitis, receiving biological therapy (Rituximab, Mepolizumab): The results of the first 8 months of the pandemic

Objective. Currently, the issues of the effect of anti-B cell therapy or inhibitor of interleukin 5 on the risk of COVID-19 infecting and outcomes in patients with ANCA-associated vasculitis (AAV) has not been completely studied. We present an analysis of the COVID-19 course and outcomes in AAV pati...

Descrición completa

Detalles Bibliográficos

Principais autores:	T. V. Beketova, V. V. Babak, M. D. Suprun
Formato:	Artigo
Idioma:	Russo
Publicado:	IMA PRESS LLC 2021-03-01
Series:	Научно-практическая ревматология
Assuntos:	covid-19 rituximab mepolizumab в-cells interleukin-5 anca-associated vasculitis granulomatosis with polyangiitis microscopic polyangiitis eosinophilic granulomatosis with polyangiitis
Acceso en liña:	https://rsp.mediar-press.net/rsp/article/view/2988
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!